Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 273

1.

Author Correction: Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 Jul 16. doi: 10.1038/s41586-019-1380-3. [Epub ahead of print]

PMID:
31308536
2.

Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.

Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, Penel N, Bompas E, Rios M, Lecesne A, Italiano A, Anract P, de Pinieux G, Collard O, BertuccI F, Duffaud F, Le Deley MC, Delaye J, Brugieres L, Blay JY.

Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32526. [Epub ahead of print]

PMID:
31246277
3.

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

4.

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R.

Cancers (Basel). 2019 Jun 4;11(6). pii: E774. doi: 10.3390/cancers11060774. Review.

5.

PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.

Bertucci F, Finetti P, Monneur A, Perrot D, Chevreau C, Le Cesne A, Blay JY, Mir O, Birnbaum D.

Mol Oncol. 2019 Jul;13(7):1577-1588. doi: 10.1002/1878-0261.12522. Epub 2019 Jun 7.

6.

Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Jul 16;:.

PMID:
31118521
7.

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.

Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.

Cancers (Basel). 2019 May 13;11(5). pii: E665. doi: 10.3390/cancers11050665.

8.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.

Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A.

J Clin Med. 2019 May 6;8(5). pii: E612. doi: 10.3390/jcm8050612.

9.

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.

Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F.

J Clin Med. 2019 Apr 30;8(5). pii: E596. doi: 10.3390/jcm8050596.

10.

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.

Daulat AM, Finetti P, Revinski D, Silveira Wagner M, Camoin L, Audebert S, Birnbaum D, Kodjabachian L, Borg JP, Bertucci F.

Br J Cancer. 2019 Apr;120(9):931-940. doi: 10.1038/s41416-019-0448-z. Epub 2019 Apr 11.

11.

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Cancers (Basel). 2019 Apr 8;11(4). pii: E497. doi: 10.3390/cancers11040497.

12.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY.

Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32307. [Epub ahead of print]

PMID:
30924137
13.

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin.

de Nonneville A, Barbolosi D, Andriantsoa M, El-Cheikh R, Duffaud F, Bertucci F, Salas S.

Cancers (Basel). 2019 Mar 26;11(3). pii: E432. doi: 10.3390/cancers11030432.

14.

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.

Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu KD, Huang S, Bertucci F, Jiang YZ, Shao ZM; Written on behalf of AME Breast Cancer Collaborative Group.

Clin Cancer Res. 2019 Mar 5. doi: 10.1158/1078-0432.CCR-18-3524. [Epub ahead of print]

PMID:
30837276
15.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

16.

ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.

Lévêque R, Corbet C, Aubert L, Guilbert M, Lagadec C, Adriaenssens E, Duval J, Finetti P, Birnbaum D, Magné N, Chopin V, Bertucci F, Le Bourhis X, Toillon RA.

Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019. Epub 2019 Feb 13.

PMID:
30771434
17.

Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls".

Bertucci F, Le Corroller-Soriano AG, Monneur-Miramon A, Moulin JF, Fluzin S, Maraninchi D, Gonçalves A.

Cancers (Basel). 2019 Feb 14;11(2). pii: E219. doi: 10.3390/cancers11020219.

18.

Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results.

Manai M, Finetti P, Mejri N, Athimni S, Birnbaum D, Bertucci F, Rahal K, Gamoudi A, Chaffanet M, Manai M, Boussen H.

Mol Clin Oncol. 2019 Feb;10(2):223-230. doi: 10.3892/mco.2018.1773. Epub 2018 Nov 26.

19.

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Nicolas E, Bertucci F, Sabatier R, Gonçalves A.

Cancers (Basel). 2018 Dec 11;10(12). pii: E506. doi: 10.3390/cancers10120506. Review.

20.

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Xerri L, Adélaïde J, Avenin M, Guille A, Taix S, Bonnet N, Carbuccia N, Garnier S, Mescam L, Murati A, Chaffanet M, Coso D, Bouabdallah R, Bertucci F, Birnbaum D.

Histopathology. 2019 Mar;74(4):654-662. doi: 10.1111/his.13783. Epub 2019 Jan 31.

PMID:
30393995

Supplemental Content

Loading ...
Support Center